Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Appetite-suppressing effects of urocortin

Oct. 11, 1996

Pravastatin continues to demonstrate clinical utility in various patient groups

Oct. 11, 1996

Generic cholestyramine cleared by FDA

Oct. 11, 1996

New hypocholesterolemic agent from Schering-Plough

Oct. 11, 1996

Second Hedgehog-based research collaboration for Ontogeny

Oct. 11, 1996

New introduction for fertility hormone

Oct. 4, 1996

Novo Nordisk and Schering AG sign collaborative agreement for fertility drugs

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...